Press release
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion by 2034, Growing at 10.3% CAGR
Biologics Contract Research Organization (CRO) Market
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced modalities such as cell and gene therapies, CRO partnerships are becoming essential to accelerate timelines and reduce costs.
In 2024, the global biologics CRO market is valued at USD 14.3 billion and is projected to reach USD 37.9 billion by 2034, growing at a CAGR of 10.3%.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/72882
Market Overview
• Market Size 2024: USD 14.3 billion
• Forecast 2034: USD 37.9 billion
• CAGR (2025-2034): 10.3%
Key Drivers
• Rising demand for biologics and biosimilars worldwide.
• Increasing outsourcing of R&D by pharma and biotech companies.
• Growing adoption of advanced therapies (cell & gene therapies, mRNA vaccines).
• Expansion of clinical trial activity in emerging markets.
• Regulatory emphasis on biologics safety and quality.
Key Challenges
• High complexity and cost of biologics development.
• Regulatory variability across regions.
• Data integrity and intellectual property protection concerns.
• Shortage of skilled professionals in biologics research.
Leading Players
IQVIA, Labcorp Drug Development, Syneos Health, ICON plc, Parexel, Charles River Laboratories, WuXi AppTec, Medpace, PPD (Thermo Fisher Scientific), and Covance.
Segmentation Analysis
By Service Type
• Discovery & Preclinical Research
• Clinical Research Services
• Laboratory Services
• Bioanalytical & Regulatory Services
• Pharmacovigilance & Post-Market Surveillance
By Therapeutic Area
• Oncology
• Immunology
• Neurology
• Infectious Diseases
• Cardiovascular Disorders
• Rare Diseases
• Others
By End User
• Pharmaceutical Companies
• Biotechnology Firms
• Academic & Research Institutes
• Medical Device & Diagnostic Companies
By Phase
• Preclinical
• Phase I
• Phase II
• Phase III
• Phase IV/Post-Marketing
Summary:
Oncology dominates therapeutic outsourcing, reflecting the biologics pipeline's heavy focus on cancer immunotherapies. However, rare diseases and infectious disease biologics are emerging as high-growth outsourcing segments.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/72882/biologics-contract-research-organization-market
Regional Analysis
• North America
The largest market, driven by strong biopharma presence, advanced infrastructure, and early adoption of CRO partnerships. The U.S. leads with extensive biologics pipelines and FDA-regulated trials.
• Europe
Significant contributor with well-established biotech clusters in Germany, the UK, and Switzerland. EMA regulations ensure strong biologics outsourcing demand.
• Asia-Pacific
Expected to record the fastest CAGR, supported by lower trial costs, large patient populations, and growing CRO infrastructure in China, India, and South Korea.
• Middle East & Africa
Emerging opportunities driven by expanding clinical research networks and government investment in healthcare.
• Latin America
Brazil and Mexico are leading markets, with rising participation in biologics clinical trials and improved regulatory frameworks.
Summary:
North America and Europe dominate revenues, but Asia-Pacific is forecasted to be the fastest-growing region through 2034 due to cost advantages and expanding clinical trial ecosystems.
Market Dynamics
Growth Drivers
1. Expanding demand for biologics, biosimilars, and advanced therapies.
2. Rising R&D outsourcing by pharmaceutical and biotech companies.
3. Increasing clinical trial complexity driving CRO partnerships.
4. Advances in AI, bioinformatics, and digital trial technologies.
5. Strong regulatory emphasis on biologics safety and efficacy.
Challenges
• High infrastructure and expertise requirements.
• Regulatory complexities across global markets.
• Data security and intellectual property risks.
• Pricing pressures due to competitive CRO landscape.
Latest Trends
• Adoption of decentralized and virtual trials for biologics.
• Integration of AI and machine learning in biologics discovery and patient recruitment.
• Growing end-to-end biologics CRO services from discovery through commercialization.
• Strategic alliances and mergers between global CROs to expand biologics capabilities.
• Focus on cell & gene therapy trials as a key future growth driver.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72884
Competitor Analysis
Key Players
• IQVIA
• Labcorp Drug Development
• Syneos Health
• ICON plc
• Parexel
• Charles River Laboratories
• WuXi AppTec
• Medpace
• PPD (Thermo Fisher Scientific)
• Covance
Competitive Landscape
The biologics CRO market is moderately consolidated, with top players like IQVIA, ICON, and Labcorp dominating global contracts. Mid-sized CROs and regional players are carving niches in specific therapeutic areas such as oncology and rare diseases. Strategic acquisitions and alliances are common as companies expand service portfolios and geographic reach.
Conclusion
The biologics CRO market is entering a high-growth phase, fueled by increasing demand for biologics, biosimilars, and advanced therapies. Valued at USD 14.3 billion in 2024, the market is projected to reach USD 37.9 billion by 2034, growing at a CAGR of 10.3%.
Future opportunities lie in adopting digital and AI-driven trial technologies, expanding end-to-end CRO services, and building specialized capabilities for cell & gene therapies. Companies that combine global reach with innovation and compliance will be best positioned to lead in this evolving biologics CRO landscape.
This report is also available in the following languages : Japanese (バイオ医薬品契約研究機関), Korean (생물학 임상시험수탁기관), Chinese (生物制剂合同研究组织), French (Organisation de recherche contractuelle sur les produits biologiques), German (Auftragsforschungsinstitut für Biologika), and Italian (Organizzazione di ricerca a contratto sui prodotti biologici), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/72882
Our More Reports:
Assisted Living Technologies
https://exactitudeconsultancy.com/reports/73188/assisted-living-technologies-market
Veterinary Hematology Analyzers
https://exactitudeconsultancy.com/reports/73190/veterinary-hematology-analyzers-market
Telerehabilitation Systems
https://exactitudeconsultancy.com/reports/73192/telerehabilitation-systems-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion by 2034, Growing at 10.3% CAGR here
News-ID: 4204298 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
Anti-CD47 Drugs Market Forecast 2034: USD 9.6 Billion, Key Players: Gilead Scien …
The global oncology landscape is rapidly evolving with breakthroughs in immuno-oncology, one of the most promising being Anti-CD47 drugs. These drugs target the CD47 protein, often referred to as the "don't eat me" signal, which allows cancer cells to evade the immune system. By blocking CD47, these therapies enable macrophages and other immune cells to recognize and destroy cancer cells. This innovation has opened new horizons in cancer treatment, particularly…
More Releases for CRO
Contract Research Organization (CRO) Research: China CRO market size is projecte …
QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report "Contract Research Organization (CRO)- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2025-2031), this report provides a comprehensive analysis of the global Wire Drawing Dies market, including market size, share, demand, industry development status, and forecasts for the next few…
Global Veterinary CRO & CDMO Market Size & Trends
According to a new market research report published by Global Market Estimates, the global veterinary CRO & CDMO market is expected to grow at a CAGR of 9.1% from 2023 to 2028.
The growing awareness regarding the importance of animal health and welfare has led to increased investments in veterinary pharmaceutical research and development. This awareness is driven by the rising concern for the well-being of pets, livestock, and animals used…
Global Contract Research Organization (CRO) Services Market
According to a new market research report published by Global Market Estimates, the Global Contract Research Organization (CRO) Services Market is expected to grow at a CAGR of 10.2% from 2023 to 2028.
The growth of the contract research organization (CRO) Services Market is fuelled by factors including the rising preference for outsourcing clinical trials, increasing investments in research and development by pharmaceutical and biopharmaceutical companies, the growing complexities in drug…
Contract Research Organization (CRO) Services Market - Efficiency, Expertise, Ex …
Newark, New Castle, USA: The "Contract Research Organization (CRO) Services Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Contract Research Organization (CRO) Services Market: https://www.growthplusreports.com/report/contract-research-organization-cro-services-market/7630
This latest report…
Biopharmaceutical CMO and CRO Market
The Biopharmaceutical CMO and CRO Market crossed US$ 32.25 billion in 2022 and is expected to hit US$ 54.13 billion by 2030, recording a CAGR of 6.5% during the forecast period
Pharmaceutical and biotech companies focus on R&D activities to innovate new molecules and therapeutic platforms to deal with chronic diseases and rare ailments; they also extensively invest in R&D activities to develop various therapeutic applications with strong medical and commercial…
Pracedo Promote Ellie Copp To CRO
Pracedo, a Mashfrog Group company that provides Salesforce consultancy and digital transformation to charities, NGOs, and enterprise customers, promotes Ellie Copp to Chief Revenue Officer.
Pracedo announced Ellie Copp as its new Chief Revenue Officer (CRO). Ellie joined Pracedo in 2019 and most recently held the position of Sales and Marketing Director. As CRO, she will continue to lead the commercial teams by overseeing all revenue-generating activities as Pracedo continues…
